iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Average Recommendation of “Hold” from Analysts

iTeos Therapeutics, Inc. (NASDAQ:ITOS) has received an average recommendation of “Hold” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $15.64.

ITOS has been the subject of a number of recent analyst reports. Raymond James Financial set a $12.00 price target on iTeos Therapeutics in a research report on Wednesday, May 14th. HC Wainwright cut shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. JPMorgan Chase & Co. cut iTeos Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wedbush restated an “outperform” rating and set a $10.50 price objective (down from $12.00) on shares of iTeos Therapeutics in a research report on Monday, July 21st. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th.

iTeos Therapeutics Trading Up 0.2%

Shares of iTeos Therapeutics stock opened at $10.17 on Monday. The company’s 50-day moving average price is $9.88 and its two-hundred day moving average price is $8.00. iTeos Therapeutics has a 52 week low of $4.80 and a 52 week high of $18.13. The stock has a market cap of $389.21 million, a PE ratio of -3.35 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14. On average, equities analysts predict that iTeos Therapeutics will post -3.49 EPS for the current fiscal year.

Insider Activity at iTeos Therapeutics

In other iTeos Therapeutics news, CEO Michel Detheux sold 43,883 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the transaction, the chief executive officer directly owned 153,903 shares of the company’s stock, valued at $1,542,108.06. The trade was a 22.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider directly owned 2,108,594 shares of the company’s stock, valued at $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,939,307 shares of company stock valued at $16,202,116. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. RA Capital Management L.P. raised its position in iTeos Therapeutics by 74.4% in the first quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company’s stock worth $21,785,000 after purchasing an additional 1,556,798 shares in the last quarter. BVF Inc. IL grew its stake in shares of iTeos Therapeutics by 32.3% in the 1st quarter. BVF Inc. IL now owns 3,075,000 shares of the company’s stock valued at $18,358,000 after purchasing an additional 750,000 shares during the period. JPMorgan Chase & Co. grew its stake in shares of iTeos Therapeutics by 342.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after purchasing an additional 1,601,477 shares during the period. 683 Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 90.6% in the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company’s stock worth $10,448,000 after buying an additional 831,883 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of iTeos Therapeutics by 15.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock worth $9,293,000 after buying an additional 163,880 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.